Immunogenicity study of low-dose administration of hepatitis B virus vaccine in newborn infants: A cost reduction trial

Different doses of hepatitis B virus vaccine—prepared by Korea Green Cross Corporation, were given to healthy infants born to HBsAg-negative mothers at birth, 1 and 6 months of age. A dose of 2 μg was administered intradermally in Group A and, in the three other groups, the vaccine was given intramuscularly (i.m.). An adequate follow-up observation was possible for 9 months after birth in 22, 25, 23 and 21 infants in Groups A, B, C and D, respecvely.
Group C (5 μg, i.m.) produced seroconversion most rapidly, showing the highest rate (96%) at 9 months of age. The lowest seroconversion rate (5%) was found at the age of 1 month in Group A subjects, but the rate increased to 91% after a booster dose was given at 6 months of age.
While it can be concluded that a 5 μg i.m. dose of vaccine at 0, 1 and 6 months of age is optimum for the immunization of infants in efficacy and economy, a 2 μg intradermal dose can also be considered as an immunogenic and economical regimen, though the immune response is slower and a special technique is required for immunization.     

44Sacral extracorporeal magnetic stimulation is an effective treatment for pelvic floor dyssynergia; Comparative study with biofeedback therapy

Background: Recent development of extracorporeal magnetic stimulation (ECMS) which uses current‐changing magnetic fields allows the induction of electrical stimulation in the desired deep tissue. Recent study showed the sacral nerve stimulation reduces corticoanal excitability that may play a functional role in anal continence mechanisms. Preliminary study shows that ECMS of sacral nerve can modify pelvic floor function and expel rectal balloon in patients with pelvic floor dyssynergia (PFD). Aims: To evaluate the effect of ECMS compared with biofeedback therapy (BF) in patients with PFD. Methods and Materials: Thirty‐eight patients who fulfilled Rome II criteria for PFD by colon transit time and anorectal function tests, were randomly treated with 8 sessions of ECMS (2/weeks; n = 19) at prone position or BF (2/weeks; n = 19) at sitting position. Stimulation parameters were set at 50–80% of maximum intensity, 10 and 50 Hz frequency, 3 s burst length with 3 and 6 s off using arm‐typed stimulator (BioCom‐1000, Mcube Co., Korea). Symptom scores for constipation with/without anorectal function test were repeatedly measured after each treatment. Response was defined as 50% or more decreased symptom score after treatment (partial response: 30–50%, poor: <30%). Results: Fifteen patients (age 49.1 ± 13.4 years, mean ± SD; 4 men) completed 8 session of BF and 14 patients (54.5 ± 17.6 years, 3 men) completed 8 session of ECMS. Four patients of BF group discontinued treatment due to unsatisfactory therapeutic effect (n = 1) and withdrew consent (n = 3) and 5 patients of ECMS group discontinued treatment because of same reasons (n = 1, 4). Total symptom scores were significantly decreased after treatment of 8 session in both treatment groups (13.4 ± 6.6 vs. 4.3 ± 4.0 for BF, p = 0.009; 14.9 ± 5.6 vs. 3.4 ± 4.0 for ECMS, p < 0.001). Bowel movements per week were also significantly increased after treatment in both groups (median 2 vs. 7 for BF, p = 0.035; median 2 vs. 7 for ECMS, p = 0.008). Thirteen out of 15 patients showed response in BF group and 12 out of 14 showed good response in ECMS group. No adverse effects in both groups. Conclusions: ECMS is as effective as BF for the treatment of PFD. Long‐term effect of ECMS for the patients with pelvic floor dyssynergia need to be evaluated in the near future.     

X线检查在小肠肿瘤诊断中的价值

小肠肿瘤在消化道肿瘤中较为少见,而且检查方法有限,目前除X线检查外,尚无其它更为有效、更清晰地显示病变及其部位、大小和范围的方法。本文收集了我院10余年来经手术及病理证实的小肠肿瘤47例,进行临床及X线分析,并对检查方法及漏诊原因等作进一步的探讨。现报告如下。1材料与方法47例患者中男性19例,女性28例,女性多于男性,平均年龄48岁,病程:1月~10年。临床症状:腹胀、腹痛24例,其中阵发性腹痛6例,2例向背部放射,绞痛3例,单有腹胀3例;呕吐5例;消化道出血19例,约占40%,其中血便6例,黑便7例,大便隐血阳性6例;腹部包块15例,约占31%;贫血头…     

The effectiveness of sub-Tenon's infiltration of local anaesthesia for cataract surgery

Purpose: To determine if adequate anaesthesia and akinesia could be obtained using an inferonasal quadrant sub-Tenons anaesthesia for cataract surgery.
Methods: The sub-Tenons method of local anaesthesia was used in 50 patients undergoing extracapsular cataract extraction and lens implantation. The technique followed was that described by JD Stevens in his study of 50 patients. Posterior sub-Tenons space was approached through a conjunctival incision in the inferonasal quadrant and the anaesthetic solution delivered by an irrigating cannula. The patients were assessed for residual ocular movements just before surgery. Effectiveness of anaesthesia was assessed during surgery using a verbal pain rating score. Scoring was based on the concept of a visual analogue pain score chart.
Results: Total akinesia was obtained in 20% patients and total anaesthesia in 24% patients. The remainder of the patients had adequate akinesia and anaesthesia to proceed with and complete the surgery.
Conclusion: This method provides satisfactory anaesthesia for cataract surgery.     

利用比较基因组杂交技术分析横纹肌肉瘤中染色体基因组的变化特征

目的 探讨横纹肌肉瘤(RMS)基因组DNA的变化特征.方法 在一步法RT-PCR检测所有标本PAX3/PAX7-FKHR mRNA融合基因表达情况的基础上,应用比较基因组杂交技术分析25例原发性RMS患者,其中腺泡状横纹肌肉瘤(ARMS)10例,胚胎性横纹肌肉瘤(ERMS)12例,多形性横纹肌肉瘤(PRMS)3例.根据融合基因表达情况、组织学分型、临床分期、组织学分级、性别和年龄进行分组比较.同时收集RMS细胞株A204(腺泡型)、RD(胚胎型)作为对照.结果 25例RMSCGH分析结果显示:(1)RMS中发生DNA拷贝数扩增最常见的部位是2p和12q,其他依次为6p、9q、10q、1p、2q、6q、8q、15q和18q(30%),发生DNA拷贝数丢失最常见的部位是3p、11P和6p(30%).(2)ARMS扩增最常见的染色体臂是12q、2p、6、2q、4q、10q和15q(30%),缺失最常见的染色体臂是3p、6p、1q、5q(30%);ERMS扩增最常见的染色体臂是7p、9q、2p、18q和1 p、8q(30%),缺失最常见的染色体臂是11p.基因组变化在不同的组织学分类中差异无统计学意义(P0.05).(3)伴有融合基因组扩增最常见的染色体臂是12q、2、6、10q、4q和15q(30%),缺失最常见的染色体臂是3 p、6p、5q(30%);不伴有融合基因组扩增最常见的染色体臂是2p、9q、18q(30%),基因组缺失最常见的染色体臂是11p和14q(30%).12q扩增在这两组间的差异有统计学意义(P<0.05),并多见于伴有融合基因的RMS.(4)在临床分期分组中,9q扩增在Ⅱ期和Ⅲ～Ⅳ期间差异有统计学意义(P<0.05),且多见于Ⅱ期患者.结论 (1)2p、12q、6p、9q、10q、lp、2q、6q、8q、15q、18q扩增及3p、11p、6p缺失可能与RMS发病相关;(2)12q扩增可能与融合基因相关;(3)9q扩增可能与RMS发病早期有关.     

Induction of APOBEC3G in human hepatoma cells by interferon-α stimulation

To clarify the role of APOBEC3G (A3G) in cellular defense against hepatitis B virus ( HBV), the expression of A3G in normal human liver and the regulation of the A3G expression in hep-atoma cell line (HuH-7) were investigated. Expression level of APOBEC3s mRNA in human liver was determined by RT-PCR. HuH-7 and HepG2 cells were treated with various concentrations of IFN-α(0 U/ml, 100 U/ml, 500 U/ml, 1000 U/ml)for 12 h. The mRNA levels were measured by a quantitative RT-PCR, the results were normalized relative to the specimens without IFN-αstimulation. Total protein of HuH-7 cells treated with various concentrations of IFN-αfor 48 h was subjected to Western blot analysis. For reporter gene assay, HuH-7 cells were transfected with the reporter plasmids containing IRF-E sites and its mutants with different lengths. Then the cells were treated with or without 1200 U/ml IFN-a for additional 12 h (1000 U/ml) after 24 h of transfection, and the cell lysate was prepared and assayed for luciferase activity. It was found that normal human liver expressed the mRNA of A3G. A3G mRNA expression in HuH-7 and HepG2 cells were up-regulated by IFN-αstimulation in a dose-depen-dent manner. Western blot analysis indicated that A3G protein expression was also enhanced by IFN-αstimulation. Sequence analysis showed the existence of putative sites of IFN regulatory factor element (IRF-E) in 5' region of A3G gene upstream the initiation codon. IFN-αstimulation results in 6- to 8-fold increase in luciferase activity in cells transfected with the plasmid containing IRF-E sites of the 5' upstream sequences, whereas luciferase activity did not change in cells transfected with the plasmid containing mutant IRF-E sites or without IRF-E sites. As a conclusion, A3G are expressed in normal human liver. A3G expression was up-regulated by IFN-αstimulation in hepatoma cells and could be involved in host defense mechanisms against HBV. ERF-E site in 5' region of AP0BEC3G gene upstream the initiation codon plays an important role in this process.     

菏泽市1992～2003年疟疾病例调查分析

山东省菏泽市于 1988年达到部颁基本消灭疟疾标准后 ,每年仍有少数疟疾病例发生。为了解其发病特点及规律 ,做好灭疟后期监测工作 ,为制订防治对策提供依据 ,现对1992～ 2 0 0 3年菏泽市发生的疟疾病例分析如下。1　材料和方法疟疾病例均经市县 (区 )中心镜检站血检疟原虫阳性确诊或症状典型经抗疟药试验治疗有效者。全部疟疾病例由县 (区 )防疫站与乡镇防保站专业人员 ,按山东省统一要求进行询问调查、填写个案病例调查卡片和处理病灶点。2　结果2 1疟疾病例分类1992～ 2 0 0 3年共接报 5 0例疟疾病例。其中间日疟 4 6例 ,恶性疟 4例 ;当…     

正交设计优选迭鞘石斛多糖提取工艺

目的:优化迭鞘石斛多糖的提取工艺.方法:以苯酚-硫酸比色法测定的多糖的含量为指标,通过正交设计L9(34)优化迭鞘石斛多糖的提取工艺.结果:迭鞘石斛多糖的最佳提取工艺为A3B2C3,即300mL水,回流3次,每次1.5h.结论:加水量、回流时间、回流次数均对样品提取多糖的含量有显著性影响,其影响的程度依次为回流次数＞回流时间＞加水量.     

Vitiligo in children and adolescents: association with thyroid dysfunction

Background The clinical characteristics of vitiligo in children and adolescents with an emphasis on thyroid dysfunction have only been reported in a few studies. Objective The purpose of this study was to examine the characteristics of children and adolescents with vitiligo and compare the incidence of thyroid dysfunction between them and controls without vitiligo at the same age. Methods A retrospective analysis of 324 Korean children and adolescents with vitiligo was performed. The results of thyroid function screening tests in them (n = 254) were compared with controls (n = 122). Results Of the total 324 children and adolescents with vitiligo, vitiligo vulgaris was the most common type (42.3%) and the most commonly involved site was the face (54.6%). A total of 15 of 254 (5.9%) patients screened for thyroid function were diagnosed with thyroid disease (four had Hashimoto’s thyroiditis; two, Graves’ disease; seven, subclinical hypothyroidism; and two, subclinical hyperthyroidism). None of the 50 patients with segmental vitiligo showed any thyroid dysfunction (P = 0.047). There was no significant difference in the incidence of thyroid disease between children and adolescents with vitiligo and the control group, in which seven of 122 (5.7%) showed thyroid dysfunction. Conclusion In this study, we demonstrated the characteristics of children and adolescents with vitiligo and also observed no significant difference in the incidence of thyroid disease between children and adolescents with vitiligo and the control group.